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Abstract
Objective: Trust is a vital component of the patient-provider relationship. Higher trust is associated with increased
adherence to treatment and improved outcomes. The purpose of this study was to compare colorectal cancer (CRC)
survivors' reported trust toward their primary care physician (PCP) and oncologist (ONC).
Methods: CRC survivors (n=62) were surveyed using the Trust in Oncologist (TiOS) instrument that assessed five
domains (honesty, fidelity, caring, competence, and global/overall) using a 5-point Likert scale. Social and
demographic variables were analyzed using nonparametric tests.
Results: Mean trust was higher toward the ONC compared to the PCP across all TiOS domains (P=0.001-0.023).
Trust was lowest in the competence and caring domains for both ONC and PCP. Younger age was associated with
lower trust compared to older age (P=.0002, P=0.018). Higher cancer stage was associated with significantly lower
trust toward PCP (P=0.074).
Conclusion: Results confirm the importance of trust between cancer patients and physicians. Although CRC
survivors report high overall trust toward their oncologist, they do not always believe their oncologist is competent
to treat their disease. We propose the novel concept of Forced Attachment Theory to explain the phenomenon of an
obligated sense of attachment from CRC patients toward their treating physicians.

Background
Colorectal cancer is the third leading cause of cancer-related deaths in men and in women, and the second leading
cause of cancer deaths when men and women are combined (1). The American Cancer Society has estimated 104,270
new cases of colon cancer and 45,230 new cases of rectal cancer for 2021. Nebraska maintains a largely rural
population, with the latest data from the Nebraska Cancer Registry reporting 4,527 residents diagnosed between 2011
and 2015, resulting in 1,692 deaths (2). Both rural and urban cancer populations face barriers in screening and access
to care (3,4).
Patient trust in a physician has been defined as 'the belief that a doctor is working in the patients' best interests' (5) as
well as the optimistic acceptance of the vulnerable situation in which patients believe that the physician cares for their
interests (6). Although trust can be interchanged with confidence, trust can often involve higher emotions and is
therefore less rational (7). Several degrees of trust and distrust occur within interpersonal relationships. The concept
of distrust is the expectation of negative or harmful behaviors and is unique from low trust, which entails the absence
of beneficial action. Considering the variations and degrees of trust, it is possible for patients to simultaneously hold
a certain amount of trust and a certain amount of distrust toward a physician (8).
Previous research suggests that higher patient trust is associated with adherence to care plans, desirable treatment
outcomes, increased patient satisfaction, and an increase in clinical trial participation (7,9-11). However, the complex
dynamics affecting patient trust between colorectal cancer patients and their primary care physicians and oncologists
have not previously been studied. There is a need to examine trust in the patient-provider relationship to provide a
higher quality of care to cancer patients.
Previous studies have identified trends between levels of trust and a variety of variables. Specific populations have
been identified to have abnormally higher or lower levels of provider trust. Compared with Non-Hispanic White
patients, Non-Hispanic Black and Hispanic patients report a lower degree of trust with their healthcare providers (1214). In studies assessing trust in prostate cancer patients, Non-Hispanic Black patients were found to have greater
variability in self-reported levels of patient-provider trust when compared to Non-Hispanic White patients (15).
Distrust (the opposite of trust) has been found to have a negative and pervasive impact on health-seeking behavior
(16). Distrust of the healthcare system has been found to be significantly correlated with age in breast cancer patients
(16,17). Other studies have found that marital status has a measurable effect among Non-Hispanic White men, with
mistrust greater in those that were married. Levels of low trust have also been found to be related to fewer quality
interactions with providers (12).
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There are discrepancies between earlier studies regarding gender and trust, with both positive and neutral relationships
reported (18). Two studies of patients with rheumatic disease found female gender to be related with higher levels of
trust (13,19). Older age has been associated with higher trust in five studies (20-23). Lower education was found to
be correlated with higher trust (21,23).
Patients diagnosed with colorectal cancer often rely on a wide range of social support provided by family, friends,
primary care providers, and oncology specialists (24). Colorectal cancer patients depend on their oncologist as a
primary source of information but rely on family physicians to fill in gaps in understanding and provide additional
support (24). Rural patients with high levels of trust in their physicians occasionally rely entirely on the
recommendations made by their primary care physician concerning their treatment decisions as opposed to their other
treating physicians (25). Previous studies have suggested a research gap due to potential differences in the levels of
trust felt by patients for their primary care physicians versus their oncologists (8).
Considering this gap in patient trust toward primary care providers compared to their oncologist, we theorize that
cancer patients may report varying levels of trust due to the unique nature of these relationships. Identifying properties
and factors of trust for colorectal cancer patients is essential considering the severity of the disease and the associated
dependence that is required from the patient to adhere to care guidance (8,26). Further research is warranted due to
the life-threatening nature of this disease and combined essential need for trust from the patient toward the physician
(8).
Based on the findings from current literature, there is a need for further research to examine levels of trust in colorectal
cancer survivors. Previous research suggests that oncologists play a different role within the patient care relationship
than primary care physicians, indicating the need to examine possible differences in patient-provider trust. This study
is novel in that patient-reported levels of trust have not been assessed in this population to our knowledge, nor have
levels of trust been compared between different types of providers. We hypothesize that there will be observable
differences between measurable survey values in patient-provider trust between primary care physicians and
oncologists as well as differences associated with demographic variables.
Methods
Data Source
This study utilized information that was available from an existing patient database maintained by the University of
Nebraska Medical Center (UNMC). Participants (age 19+, n=62) were previously recruited into the iCaRe 2 database
registry (IRB 253-13 EP) with a confirmed primary colon, rectal, or colorectal diagnosis in the state of Nebraska
within the last ten years. Participants were characterized by rural or urban status based on their FIPS code of primary
residence using the CDC Urban-Rural Classification Scheme by County published in 2013. For consistency, each
patient was provided with two copies of the TiOS; 1) to be completed about their primary care physician, 2) to be
completed about their oncologist.
The iCaRe2 biorepository was developed and is governed by UNMC to maintain and track cancer patients, patients
who are at a high risk of developing cancer, and healthy control individuals. The registry contains patient
demographics such as age, gender, and place of residence, as well as medical data and socioeconomic characteristics,
including education and income. The registry collects two baseline disease-specific questionnaires at the time of
diagnosis to procure additional patient information.
Study Design
This is a cross-sectional, observational study utilizing survey data to examine levels of patient trust.
Study Population and Sampling
All participants with a confirmed primary diagnosis of colon or rectal cancer were eligible for this study. This included
males and females of all races and ethnicities (aged 19+) with a primary colon or rectal diagnosis of any stage. No
limitations were set regarding dates of diagnosis or medical history. Factors that could complicate the recruitment
process included physician communication skills, number of comorbidities, having been in remission, number of visits
to the physician in the last 12 months, recent metastasis, and age at diagnosis. These factors have been theorized as
variables that may alter how patients feel about their physicians, and therefore their willingness to participate.
Participants were emailed a copy of the TiOS questionnaire if a current email address was listed in the medical records.
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For patients without listed email addresses, a paper version of the TiOS questionnaire was mailed to their residence
or provided during a clinic visit. All eligible participants (n = 173) were invited to participate in this study (Figure 1).
This study was approved by the University of Nebraska Medical Center Institutional Review Board (IRB Ref no: 01018-EP) and written informed consent was obtained for all study participants.
Materials
Extensive demographic information had been previously recorded in the registry prior to the start of this study. The
first iCaRe2 core questionnaire contains socio-demographic factors (age, gender, race, ethnicity, chemical exposure,
lifestyle factors), while the second extended module questionnaire collects disease-specific factors (symptoms,
medical history, family medical history, validated quality of life survey - SF-36). Clinical data, such as primary cancer
site, tumor histology, stage, dates of diagnosis, and dates of treatment, are collected by iCaRe2 personnel from the
medical records and logged into the database.
Numerous survey instruments have been developed to assess and explore the complex patient-provider relationship
and the role that trust plays. The Trust in Physician Scale (27) was developed to measure patient trust in the primary
care provider and predates the TiOS. The Patient Trust Scale (28) was constructed to incorporate changes in the
healthcare system, specifically the transition to managed care (29). A recently developed instrument, the Physician
Trust Scale (7), is currently the highest utilized instrument for measuring trust. All three of these instruments were
developed in the primary care setting and measure reported levels of patient trust toward the primary care physician.
In contrast, the Trust in Oncologist Scale (TiOS) was created to assess cancer patient satisfaction and trust in health
care (30). The instrument utilizes the four main domains from the previously validated 10-item Trust in Physician
Scale (7) of "competence, fidelity, confidentiality, and honesty." During the development of the TiOS, an additional
domain of "caring" was added based on patients' accounts of trust obtained from qualitative research (30). This
additional domain is important because the existing dimensions did not fully capture patients' constructions of trust,
nor did these domains capture the oncologist's expression of involvement, sympathy, and attention to the patient.
Using the TiOS, an overall trust score can be obtained by averaging the responses, with higher scores indicating higher
trust. Previous studies have found that patients are able to distinguish between the different aspects of trust (domains),
allowing investigation within and between individual core trust domains (30).
The TiOS was validated in two studies (first in Dutch and then in English) using confirmatory factor analysis,
exploratory factor analysis, measurement of internal consistencies, and calculation of Spearman's correlations between
the instrument and known correlates. These correlates were satisfaction, trust in health care, and the number of
previous consultations with the oncologist.
The TiOS employs 18 items to measure a cancer patient's trust in their oncologist along five domains: global,
competence, fidelity, honesty, and caring. Internal consistency was assessed with a Cronbach's alpha of .94 (30). All
18 items of the scale consisted of questions using a 5-point Likert answering scale ('strongly disagree' (1) to 'strongly
agree' (5) (30). For example, "Your doctor is very careful and precise" is a question item measuring the competence
domain. Mean trust (range 1-5) is calculated by averaging the responses. Three items are phrased in a negative context
to provide reverse-coded questions. In addition to the 18-items on the TiOS survey, an open-ended answer box was
included on the survey for this study. Adding this qualitative measurement allowed patients the opportunity to express
concerns not measured by the survey and provide additional information for analysis. Table A (Supplemental) shows
an overview of all items and dimensions of the TiOS, including the breakdown of dimensions into the five primary
domains.
Statistical Methods
Central tendency distributions and frequencies were used to examine the study population prior to analysis. Mean
scores were analyzed from both the oncologist and PCP survey results. Internal reliability was assessed prior to
statistical analysis and found to be strong with a Cronbach's alpha of 0.942 for the oncology instrument and 0.965 for
the PCP instrument.
Descriptive statistics for categorical variables included frequencies and percentages. For continuous variables,
descriptive statistics included the mean, quartiles, and minimum/maximum. The relationship of five demographic and
background variables with the difference in each subscale score were examined. Nonparametric and ANOVA tests
were used to examine differences in subscales for the variables age, gender, primary cancer type (colon/rectal), history
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of secondary cancer (yes/no), and cancer stage (0, I, II, III, IV). Mean differences in each subscale (global, competence,
honesty, fidelity, and caring) were calculated to compare differences in average trust scores between the oncologist
and PCP survey instruments. SPSS version 26 and PC SAS version 9.4 were used for the analysis. The statistical level
of significance was set to 0.05 for all analyses.
Results
Demographics (Table 1) for the study population were 87% Non-Hispanic White with 43% of the population aged
19-64 (n=27) and 57% of the population over the age of 65 (n=36). The majority of study participants were female
(n=35), and 75% with a history of colon cancer (n=48) versus 24% with a history of rectal cancer (n=15). Interestingly,
37% of study participants (n=24) were also diagnosed with a second primary cancer other than colon or rectal. Study
participants ranged in cancer stage from 0-IV and were stratified into three categories for this study 1) stages 0, I, II
represented 43% of the total population (n=27), 2) stage III represented 32% of the total population (n=21), and 3)
stage IV accounted for 24% of the study population (n=15). The mean length of time from date of CRC diagnosis to
study participation was 2086 days (Range = 468-5658 days).
Patient-reported scores are shown in Table 2 for the ONC and PCP survey instruments. Mean trust scores were
consistently reported higher toward the oncologist than toward the primary care provider, and found to have a
statistically significant difference. The global domain displayed the highest mean difference (Md=0.298, P=0.001)
and suggests that CRC survivors feel stronger overall levels of trust toward their oncologist over their PCP. The second
highest mean difference was found in the competence domain (Md=0.238, P=0.007), suggesting that CRC survivors
may feel that their oncologist is more competent in their medical practice skills than their PCP.
Additional analyses using the overall global domain were conducted to determine if demographic variables of age,
gender, primary cancer site, the presence of a secondary cancer, stage, or geographic area were associated with higher
or lower levels of self-reported trust (Table 3). CRC survivors stratified into the higher age group of ≥65 reported
higher levels of trust toward both their oncologist and PCP (M= 4.857; M=4.571) when compared to CRC survivors
stratified into the lower age group of ≤64 (M= 4.389, P=0.002; M=4.074, P=0.018). Survivors were stratified into
staging subgroups to determine if an earlier or later stage diagnosis was associated with levels of trust. CRC survivors
with stage 0-II disease reported higher levels of trust toward both their oncologist and PCP (M=4.704; M=4.574), with
self-reported trust scores decreasing as the survivor's cancer stage increased. Trust scores between these staging
subgroups were found to be statistically significant, with trust being consistently reported higher toward the oncologist
than the PCP.
Further extrapolation (Table B Supplemental) of all domains across the variables of interest found several domains
associated with significant impact on self-reported trust. Confirming previously suggested results, the global domain
of overall trust was associated with higher trust in survivors toward their oncologist under the age of 64 (ONC
M=4.388, P=0.001), while survivors over the age of 65 (M=4.388, P=0.001) reported higher trust toward their PCP.
Female CRC survivors reported higher scores in the honesty (M=4.764, P=0.002) and fidelity (M=4.723, P=0.014)
domains toward their oncologist when compared to male CRC survivors. Survivors with colon cancer reported higher
trust in the competence domain toward their PCP than rectal cancer survivors (M=4.196, P=0.084).
The presence of a secondary cancer diagnosis was associated with two separate domains of trust. Survivors with a
secondary cancer reported lower levels of trust toward their oncologist in the honesty domain than survivors without
a secondary cancer diagnosis (M=4.478, P=0.062). Survivors diagnosed with a secondary cancer also reported lower
levels of trust in the fidelity domain toward their PCP than survivors without a second primary cancer diagnosis
(M=4.260, P=0.06). Consistent with previous results, the association between a higher cancer stage and lower levels
of trust was found in the global domain toward the oncologist (M=4.703, 4.650, 4.566, P=0.009).
Discussion
When comparing self-reported trust from CRC survivors toward their oncologist versus their primary care provider,
we found that scores were consistently higher toward the oncologist across all domains of the Trust in Oncologist
Scale. The global domain represents "the irreducible soul of trust, and includes aspects that combine elements from
some or all of the separate dimensions" (8). The reported mean difference in trust in the global domain (P= 0.001)
suggests that cancer patients feel a deeper trust in their oncologist that includes a combination of aspects from the
fidelity, honesty, caring, and competence domains.
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The significant decrease in reported trust for the competence domain is an important result of this study (P=0.007).
This suggests that CRC survivors do not feel confident in the medical and interpersonal skills of their PCP. Previous
studies have found that competence is part of the necessary foundation of trust in the patient-provider relationship (8).
The NCCN Guidelines for Survivorship provide recommendations for developing Survivorship Care Plans (SCPs) for
cancer survivors that integrate care across care-disciplines (31). Primary Care Providers serve a key role in the
multidisciplinary application of SCPs with the goal of facilitating care coordination and improving health outcomes
of survivors. These results advocate for improved communication between PCPs and their patients to increase trust
within these relationships.
The stratification of cancer stage in this study provided an opportunity to explore how survivors in varying stages of
disease progression related to their physicians. As CRC stage increased, levels of self-reported trust decreased toward
both the oncologist and PCP. We theorize several possibilities for this outcome. First, earlier studies have explored
the theory of attachment as a model that attempts to describe the dynamics of interpersonal relationships between
people. This model specifically focuses on the strong emotional and physical attachment that is formed between a
patient and caregiver (or, in this circumstance, a physician caring for a patient). Insecurely attached patients trust their
physicians less and are associated with a decreased satisfaction in their physician than patients who were securely
attached (32). We theorize that CRC survivors may feel an obligated sense of attachment toward their treating
physician during their cancer journey of diagnosis and treatment. We introduce Forced Attachment Theory as a novel
theory to explain this phenomenon. This patient-physician attachment dynamic changes the longer that a patient
receives care for ongoing cancer burden or progression of disease; resulting in a decrease in reported trust as cancer
stage increases. Previous studies supporting this theory have proposed that the severity of cancer disease may play a
role in how patients report trust (33).
Survivors diagnosed with late-stage (AJCC IV) and metastatic disease (AJCC IV) reported lower trust toward their
oncologist and PCP, suggesting a possible correlation between length of treatment time and aggression of disease to
a less trusting relationship between patient and physician. The average length of time for patients in this study from
date of diagnosis to date of survey completion was 2086 days or 5.71 years. Although this study did not have a
sufficient sample size to extrapolate data by length of survivorship, this preliminary data suggests a need for additional
research to better understand this association.
Study Limitations
There were several limitations of this study, the first being the recruitment of a convenience sample that may not have
fully represented the average population of CRC survivors in the state of Nebraska. The majority of study participants
were Non-Hispanic White females with colon cancer. The minimal variation in demographic and social characteristics
may reduce the generalizability of the results to other populations. A second limitation is that cancer survivors were
only asked to self-report their feelings of trust toward their oncologist and not toward the rest of their oncology team.
Third, the Trust in Oncologist instrument is relatively new when compared with older trust instruments; therefore, this
research is limited in its comparability to other studies across a broader disease spectrum.
Clinical Implications
Results suggest that colorectal cancer patients are able to differentiate between multiple domains of trust, particularly
in the competence of their oncologist (and corresponding larger physician team) to treat their disease.
Multidisciplinary teams (MDT) in oncology are becoming standard in the treatment of colorectal cancer. Previous
research has found that adequate MDT processes are associated with improved survival for patients with colorectal
cancer (34). Future studies should explore the complex interpersonal relationships that form between these MDTs and
patients, with a focus on how trust impacts these dynamics to better inform clinical practice.
Future research should seek to further understand the impact of trust in the patient-provider relationship as well as the
various factors that influence trust. In this study, a small subgroup of survivors responded to the request for study
participation with the sole purpose of declining due to a poor or lack of patient-provider relationship. For future
discussion, the medical data for this subset of the population should be examined to draw possible inferences for this
behavior and the consequences resulting from this negative relationship. Participant responses to the Trust in
Oncologist Scale should be correlated with the length and quality of their provider relationship as these could
significantly influence trust values. Additionally, there is a future opportunity to analyze qualitative data from similar
cancer patient populations to gain a better understanding of trust perspectives.
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Conclusion
The TiOS instrument has had minimal use on an international scale but has already proven to be a valuable addition
to the collection of metrics available to examine trust. This study focused primarily on colon and rectal cancer;
however, patients with other cancers (for example, breast, prostate, leukemia) may have differing levels of trust due
to the unique aspects of their individual disease burden. Future research should build upon the foundation established
here and continue to explore our theory of Forced Attachment in cancer patients. To our knowledge, the Trust in
Oncologist Scale has never been utilized in the United States or within a CRC population that is primarily in the posttreatment and long-term phase of their survivorship journey. The results from this study should inform physicians and
provider care teams on the importance of interpersonal skills and building quality relationships founded on trust with
their patients.
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